First human tests: how does a new drug act in damaged livers?
NCT ID NCT07401862
Summary
This early-stage study aims to understand how a new drug, eloralintide, is processed by the body in people with varying degrees of liver damage. Researchers will compare its effects in 36 participants with mild, moderate, or severe liver impairment to those with normal liver function. The main goal is to check how the drug moves through the body and to identify any side effects, which will help determine safe dosing for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Research Corporation
RECRUITINGSan Antonio, Texas, 78215, United States
Contact Phone: •••-•••-••••
Contact
-
CRU Early Phase Unit
NOT_YET_RECRUITINGKistarcsa, H-2143, Hungary
Contact Phone: •••-•••-••••
Contact
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.